**A      J&J PHARMA CORPORATION**

|  NEVADA                                                                                           |  86-1024812                                                       |
|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
|  (State                  or other jurisdiction of                  incorporation or organization) | (I.R.S.                  Employer Identification                  No.) |

----

| **A                    J&J PHARMA CORPORATION**                    |
|------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE                  ENTERPRISE)** |

|   TABLE                    OF CONTENTS |
|--------------------------------------------------|
|                                             |   |   |   |   |   |   |   |   |
|                                             |   |   |   |   |   |   |   | Page |
| Part                    I                        | Financial                    Information | 3 |
|                                             |   |   |   |   |   |   |   |   |
| Item                    1.                       | Financial                    Statements: | 3 |
|                                             |   |   |   |   |   |   |   |   |
|                                             | Condensed                    Balance Sheets March 31, 2006 (unaudited) and December 31, 2005 |  3 |
|                                             |   |   |
|                                             | Unaudited                    Condensed Statements of Operations for the three months ended                    March 31,                    2006 and 2005, and cumulative from inception on December 31,                    1998 through                    March 31, 2006 |  4 |
|                                             |   |   |
|                                             | Unaudited                    Condensed Statements of Cash Flows for the three months ended                    March 31,                    2006 and 2005, and cumulative from inception on December 31,                    1998 through                    March 31, 2006 |  5 |
|                                             |   |   |
|                                             | Statement                    of Stockholders' equity for the period from December 31, 1998                    to March 31,                    2006 (unaudited) |  6 |
|                                             |   |   |
|                                             |  Notes                  to Financial Statements (unaudited) |  7 |
|                                             |   |   |
| Item                    2.                       |  Plan                  of operation |  7 |
|                                             |   |   |
|  Part                  II                   |  Other                  Information |  7 |
|                                             |   |   |
|  Item                  1.                   |  Legal                  Proceedings |  7 |
|                                             |   |   |
|  Item                  2.                   |  Changes                  in Securities |  7 |
|                                             |   |   |
|  Item                  6.                   |  Exhibits                  and Reports on Form 8-K |  7 |
|                                             |   |   |
|                                             |  Signatures |  7 |
|                                             |   |   |
|                                             |  Certifications |  8 |

----

| **A                      J&J PHARMA CORPORATION**                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**                                                                                        |
| **CONDENSED                  BALANCE SHEETS**                                                                                                |
|                                                                                                                                         |
|                                                                                                                                         |   |   |   |   |   |   |   |
|                                                                                                                                         |   |   | March                  31,  |   |   | December                  31, |   |
|                                                                                                                                         |   |   | 2006 |   |   | 2005 |   |
|                                                                                                                                         |   |   | (unaudited)  |   |   |   |   |
| **ASSETS**                                                                                                                                   |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
| CURRENT                  ASSETS                                                                                                              |   | $ | - |   | $ | - |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
| **LIABILITIES                  AND STOCKHOLDERS' EQUITY (DEFICIT)**                                                                          |
|                                                                                                                                         |   |   |   |   |   |   |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
| CURRENT                  LIABILITIES                                                                                                         |   |   |   |   |   |   |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
|     Accounts                  payable, Officers                                                                          |   | $ | 35,816 |   | $ | 33,128 |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
|     Total                  Current Liabilities                                                                           |   |   | 35,816 |   |   | 33,128 |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
| COMMITMENTS                  AND CONTINGENCIES                                                                                               |   |   |   |   |   |   |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
| STOCKHOLDERS'                  EQUITY (DEFICIT)                                                                                              |   |   |   |   |   |   |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
| Common                      stock, par value $.001, 25,000,000 shares authorized, 1,000,000                      issued and outstanding |   |   | 1,000 |   |   | 1,000 |   |
| Paid                  in capital                                                                                                             |   |   | 1,800 |   |   | 1,800 |   |
| (Deficit)                  accumulated during the development stage                                                                          |   |   | (38,616 | ) |   | (35,928 | ) |
|                                                                                                                                         |   |   |   |   |   |   |   |
|                                                                                                                                         |   |   |   |   |   |   |   |
| Total                  Stockholders' Equity (Deficit)                                                                                        |   |   | (35,816 | ) |   | (33,128 | ) |
|                                                                                                                                         |   |   |   |   |   |   |   |
|                                                                                                                                         |   | $ | -  |   | $ | - |   |
|                                                                                                                                         |   |   |   |   |   |   |   |

----

| **A                      J&J PHARMA CORPORATION**   |
|---------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**   |
| **CONDENSED                  STATEMENTS OF OPERATIONS** |
|  (**unaudited)**                                   |
|                                                    |   |   |   |   |   |   |   |   |   |   |
|                                                    |   |   |   |   |   |   |   |   | Cumulative  |   |
|                                                    |   |   |   |   |   |   |   |   | from  |   |
|                                                    |   |   |   |   |   |   |   |   | July                  16,  |   |
|                                                    |   |   |   |   |   |   |   |   | 1998 |   |
|                                                    |   | Three                  Months Ended  |   | (Inception) |   |
|                                                    |   | March                  31,   |   | to |   |
|                                                    |   |   | 2006 |   |   | 2005 |   |   | March                  31, 2006 |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |
| REVENUES                                                |   | $ | - |   | $ | - |   | $ | - |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |
| EXPENSES                                                |   |   |   |   |   |   |   |   |   |   |
| General                  and administrative             |   |   | 2,688 |   |   | 2,455 |   |   | 38,616 |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |
| Total                  expenses                         |   |   | 2,688 |   |   | 2,455 |   |   | 38,616 |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |
| NET                  (LOSS)                             |   | $ | (2,688 | ) | $ | (2,455 | ) | $ | (38,616 | ) |
|                                                    |   |   |   |   |   |   |   |   |   |   |
| NET                  (LOSS) PER SHARE                   |   |   | * |   |   | * |   |   |   |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |
| WEIGHTED                  AVERAGE NUMBER OF             |   |   |   |   |   |   |   |   |   |   |
| COMMON                  SHARES OUTSTANDING              |   |   | 1,000,000 |   |   | 1,000,000 |   |   |   |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |
|                                                    |   |   |   |   |   |   |   |   |   |   |
| *                  less than $ (0.01) per share         |   |   |   |   |   |   |   |   |   |   |

----

| **A                      J&J PHARMA CORPORATION**                                        |
|----------------------------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**                                        |
| **CONDENSED                  STATEMENTS OF CASH FLOWS**                                      |
| **(unaudited)**                                                                              |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
|                                                                                         |   |   |   |   |   |   |   |   | Cumulative  |   |
|                                                                                         |   |   |   |   |   |   |   |   | from  |   |
|                                                                                         |   |   |   |   |   |   |   |   | July                  16,  |   |
|                                                                                         |   |   |   |   |   |   |   |   | 1998 |   |
|                                                                                         |   | Three                  Months Ended  |   | (Inception) |   |
|                                                                                         |   | March                  31,   |   | to |   |
|                                                                                         |   |   | 2006 |   |   | 2005 |   |   | March                  31, 2006 |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **OPERATING                  ACTIVITIES**                                                    |   |   |   |   |   |   |   |   |   |   |
|     Net                  (loss) from operations                          |   | $ | (2,688 | ) | $ | (2,455 | ) | $ | (38,616 | ) |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **NET                  CASH (USED BY) OPERATING ACTIVITIES**                                 |   |   | (2,688 | ) |   | (2,455 | ) |   | (38,616 | ) |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **FINANCING                  ACTIVITIES**                                                    |   |   |   |   |   |   |   |   |   |   |
|     Shareholder                  advances                                |   |   | 2,688 |   |   | 2,455 |   |   | 35,816 |   |
|     Proceeds                  from                  sale of common stock |   |   |   |   |   |   |   |   | 2,800 |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **NET                  CASH PROVIDED BY FINANCING ACTIVITIES**                               |   |   | 2,688 |   |   | 2,455 |   |   | 38,616 |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **NET                  INCREASE IN CASH**                                                    |   |   | - |   |   | - |   |   | - |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **CASH,                  BEGINNING OF PERIOD**                                               |   |   |   |   |   |   |   |   | - |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |
| **CASH,                  END OF PERIOD**                                                     |   | $ | - |   | $ | - |   | $ | - |   |
|                                                                                         |   |   |   |   |   |   |   |   |   |   |

----

| **A                      J&J PHARMA CORPORATION**                    |
|--------------------------------------------------------------------------|
| **(A                  DEVELOPMENT STAGE ENTERPRISE)**                    |
| **STATEMENTS                  OF STOCKHOLDERS' EQUITY (DEFICIT)**        |
|                                                                     |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   | **(Deficit)**  |   |   |   |   |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   | **Accumulated**  |   |   |   |   |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   | **During                  the**  |   |   |   |   |
|                                                                     |   | **Common                  Stock**  |   | **Paid-in** |   |   | **Development** |   |   |   |   |
|                                                                     |   |   | **Shares**  |   |   | **Amount** |   |   | **Capital** |   |   | **Stage** |   |   | **Total** |   |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  at inception**                              |   |   | - |   | $ | - |   | $ | - |   | $ | - |   | $ | - |   |
| July                  16, 1998:                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Proceeds                    from sale of common stock at $.01 per share  |   |   | 200,000 |   |   | 200 |   |   | 1,800 |   |   |   |   |   | 2,000 |   |
| Proceeds                    from sale of common stock at par value $.001 |   |   | 800,000 |   |   | 800 |   |   |   |   |   |   |   |   | 800 |   |
|  Net                  (loss) for the period                         |   |   |   |   |   |   |   |   |   |   |   | (2,385 | ) |   | (2,385 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 1998**                         |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (2,385 | ) |   | 415 |   |
|  Net                  (loss) for the year                           |   |   |   |   |   |   |   |   |   |   |   | (2,985 | ) |   | (2,985 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 1999**                         |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (5,370 | ) |   | (2,570 | ) |
|  Net                  (loss) for the year                           |   |   |   |   |   |   |   |   |   |   |   | (2,985 | ) |   | (2,985 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2000**                         |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (8,355 | ) |   | (5,555 | ) |
|  Net                  (loss) for the year                           |   |   |   |   |   |   |   |   |   |   |   | (5,685 | ) |   | (5,685 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2001**                         |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (14,040 | ) |   | (11,240 | ) |
|  Net                  (loss) for the year                           |   |   |   |   |   |   |   |   |   |   |   | (4,335 | ) |   | (4,335 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2002**                         |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (18,375 | ) |   | (15,575 | ) |
|  Net                  (loss) for the year                           |   |   |    |   |   |    |   |   |    |   |   | (4,358 | ) |   | (4,358 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2003**                         |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (22,733 | ) |   | (19,933 | ) |
|  Net                  (loss) for the year                           |   |   |    |   |   |    |   |   |    |   |   | (6,605 | ) |   | (6,605 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2004**                         |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (29,338 | ) |   | (26,538 | ) |
|  Net                  (loss) for the year                           |   |   |     |   |   |    |   |   |    |   |   | (6,590 | ) |   | (6,590 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  December 31, 2005**                         |   |   | 1,000,000 |   |   | 1,000 |   |   | 1,800 |   |   | (35,928 | ) |   | (33,128 | ) |
| **(unaudited)**                                                          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  Net                  (loss) for the period                         |   |   |    |   |   |    |   |   |    |   |   | (2,688 | ) |   | (2,688 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| **Balances,                  March 31, 2006 (unaudited)**                |   |   | 1,000,000 |   | $ | 1,000 |   | $ | 1,800 |   | $ | (38,616 | ) | $ | (35,816 | ) |
|                                                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

----

**A            J&J PHARMA CORPORATION**

**(A      DEVELOPMENT STAGE ENTERPRISE)**

**NOTES      TO FINANCIAL      STATEMENTS**

**(unaudited)**

| 31.1 | Certificate                of CEO as Required by Rule                13a-14(a)/15d-14 |
|------|---------------------------------------------------------------------------------------|

| 31.2 | Certificate                of CFO as Required by Rule                13a-14(a)/15d-14 |
|------|---------------------------------------------------------------------------------------|

| 32 | Certificate                of CEO as Required by Rule Rule 13a-14(b) and Rule 15d-14(b)                (17 CFR 240.15d-14(b)) and Section 1350 of Chapter 63 of Title                18 of the United States Code |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| (a) | Designed                  such disclosure controls and procedures, or caused such disclosure                  controls and procedures to be designed under our supervision,                  to ensure that material information relating to the small business                  issuer, including its consolidated subsidiaries, is made known                  to us by others within those entities, particularly during the                  period                  in which this report is being                  prepared; |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b) | Designed                  such internal control over financial reporting, or caused such                  internal control over financial reporting to be designed under                  our                  supervision, to provide reasonable assurance regarding the reliability                  of financial reporting and the preparation of financial statements                  for external purposes in accordance with generally accepted accounting                  principles; |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c) | Evaluated                  the effectiveness of the small business issuer's disclosure                  controls and procedures and presented in this report our conclusions                  about the effectiveness of the disclosure controls and procedures,                  as of the end of the period covered by this report based on                  such evaluation; and |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d) | Disclosed                  in this report any change in the small business issuer's internal                  control over financial reporting that occurred during the small                  business issuer's most recent fiscal quarter (the small business                  issuer's                  fourth fiscal quarter in the case of an annual report) that has                  materially affected, or is reasonably likely to materially affect,                  the                  small business issuer's internal control over financial reporting;                  and |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a) | All                  significant deficiencies and material weaknesses in the design                  or                  operation of internal control over financial reporting which are                  reasonably                  likely to adversely affect the small business issuer's ability                  to record, process, summarize and report financial information;                  and |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b) | Any                  fraud, whether or not material, that involves management or other                  employees who have a significant role in the small business issuer's                  internal control over financial                  reporting. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----

| (a) | Designed                    such disclosure controls and procedures, or caused such disclosure                    controls and procedures to be designed under our supervision,                    to ensure that material information relating to the small business                    issuer, including its consolidated subsidiaries, is made known                    to us by others within those entities, particularly during the                    period                    in which this report is being                    prepared; |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b) | Designed                    such internal control over financial reporting, or caused such                    internal control over financial reporting to be designed under                    our                    supervision, to provide reasonable assurance regarding the reliability                    of financial reporting and the preparation of financial statements                    for external purposes in accordance with generally accepted accounting                    principles; |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c) | Evaluated                    the effectiveness of the small business issuer's disclosure                    controls and procedures and presented in this report our conclusions                    about the effectiveness of the disclosure controls and procedures,                    as of the end of the period covered by this report based on                    such evaluation; and |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d) | Disclosed                    in this report any change in the small business issuer's internal                    control over financial reporting that occurred during the small                    business issuer's most recent fiscal quarter (the small business                    issuer's                    fourth fiscal quarter in the case of an annual report) that has                    materially affected, or is reasonably likely to materially affect,                    the                    small business issuer's internal control over financial reporting;                    and |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a) | All                    significant deficiencies and material weaknesses in the design                    or                    operation of internal control over financial reporting which                    are                    reasonably                    likely to adversely affect the small business issuer's ability                    to record, process, summarize and report financial information;                    and |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b) | Any                    fraud, whether or not material, that involves management or other                    employees who have a significant role in the small business issuer's                    internal control over financial                    reporting. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

----